Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
- PMID: 30267352
- DOI: 10.1007/s10689-018-0106-2
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
Abstract
Hereditary predisposition is estimated to account for 10% of all pancreatic cancer cases. However, referral patterns and clinical workflow for germline testing in this disease differ significantly by institution, and many at-risk patients may not undergo appropriate counseling and testing. We undertook an analysis of patients diagnosed with pancreatic cancer (PDAC) who were referred to the Clinical Genetics program of a high-volume academic center over a 3-year period to assess referral frequency, evaluate the yield of germline testing in this selected patient cohort, and elucidate the reasons individuals did not undergo recommended germline testing. Medical records of patients with PDAC referred for genetic counseling between January 2015 and October 2017 were reviewed for demographic, medical/family history, and disease-specific data. If testing did not occur, reasons were documented. Genetic test results were categorized as negative, variants of unknown significance, or established pathogenic mutations. Descriptive statistics included means with standard deviations; associations were analyzed with t test and Fisher's exact test. 32% (137 of 432) of PDAC patients were referred for genetic counseling, but only 64% attended their appointment and 60% ultimately underwent germline testing. Common reasons for attrition included worsening disease severity, lack of patient follow-up, insurance concerns, and logistic/travel challenges. Pathogenic germline mutations were detected in 20% (16 of 82) of patients tested, distributed across races/ethnicities, and significantly associated with younger age and positive family history of breast cancer. PDAC patients frequently do not undergo genetic counseling/germline testing despite appropriate referrals, highlighting a need to develop streamlined processes to engage more patients in testing, especially those with high-risk features.
Keywords: Genetic counseling; Germline testing; Pancreatic cancer.
Similar articles
-
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.Cancer Med. 2020 Jun;9(11):4004-4013. doi: 10.1002/cam4.2973. Epub 2020 Apr 7. Cancer Med. 2020. PMID: 32255556 Free PMC article.
-
Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer.J Natl Compr Canc Netw. 2024 Jun 18;22(5):299-305. doi: 10.6004/jnccn.2023.7333. J Natl Compr Canc Netw. 2024. PMID: 38889755 Free PMC article.
-
Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.Cancer. 2019 Jul 15;125(14):2488-2496. doi: 10.1002/cncr.32077. Epub 2019 Apr 12. Cancer. 2019. PMID: 30980401
-
The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.Surg Pathol Clin. 2022 Sep;15(3):491-502. doi: 10.1016/j.path.2022.05.004. Epub 2022 Aug 2. Surg Pathol Clin. 2022. PMID: 36049831 Review.
-
Expanding access to genetic testing for pancreatic cancer.Fam Cancer. 2024 Aug;23(3):247-254. doi: 10.1007/s10689-024-00389-w. Epub 2024 May 11. Fam Cancer. 2024. PMID: 38733419 Free PMC article. Review.
Cited by
-
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies.Ther Adv Med Oncol. 2022 Sep 6;14:17588359221118019. doi: 10.1177/17588359221118019. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090800 Free PMC article. Review.
-
Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.Oncologist. 2021 Nov;26(11):e1982-e1991. doi: 10.1002/onco.13968. Epub 2021 Sep 20. Oncologist. 2021. PMID: 34506673 Free PMC article.
-
A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study.Gastroenterology. 2024 May;166(5):872-885.e2. doi: 10.1053/j.gastro.2024.01.042. Epub 2024 Feb 5. Gastroenterology. 2024. PMID: 38320723 Clinical Trial.
-
Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.Cancer Med. 2020 Jun;9(11):4004-4013. doi: 10.1002/cam4.2973. Epub 2020 Apr 7. Cancer Med. 2020. PMID: 32255556 Free PMC article.
-
Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review.Cancers (Basel). 2023 Dec 21;16(1):56. doi: 10.3390/cancers16010056. Cancers (Basel). 2023. PMID: 38201484 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical